Absci与半导体公司AMD合作开发人工智能药物-动脉网

Absci partners with semiconductor company AMD for AI drug discovery

MobiHealthNews 等信源发布 2025-01-21 18:18



可切换为仅中文







Photo:

照片：

Hero Images Inc.

Hero Images公司。

/Getty Images

/盖蒂图片

Absci

, a data-first generative AI drug creation company, is partnering with AMD, a semiconductor company, to deploy AMD Instinct accelerators and ROCm software to power vital AI drug discovery workloads, as well as Absci's advanced De Novo antibody design models.

是一家数据第一的生成性人工智能药物创建公司，正在与半导体公司AMD合作，部署AMD Institute加速器和ROCm软件，为重要的人工智能药物发现工作负载以及Absci的先进从头抗体设计模型提供动力。

In addition, AMD is making a $20 million investment in Absci. The investment will be structured as a private investment in public equity.

此外，AMD正在Absci投资2000万美元。该投资将以私募股权投资的形式进行。

The aim of the strategic partnership is to back up Absci’s mission of creating better biologics for patients faster using optimized AI solutions for complex biological modeling that offer exceptional performance, reduced infrastructure costs and faster innovation cycles.

该战略伙伴关系的目的是支持Absci的使命，即更快地为患者创造更好的生物制剂，使用优化的人工智能解决方案进行复杂的生物建模，提供优异的性能，降低基础设施成本和更快的创新周期。

'At Absci, we are always looking for ways to push the boundaries of what's possible in drug discovery,' Sean McClain, founder and CEO of Absci, said in a statement.

Absci创始人兼首席执行官肖恩·麦克莱恩（SeanMcClain）在一份声明中说，在Absci，我们一直在寻找方法来突破药物发现的可能性。

'This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available.'

“与AMD的这种合作关系为我们提供了独特的优势，即与一个坚定致力于支持我们需求的合作伙伴密切合作，同时提供最有效、创新的人工智能解决方案。”

McClain added that AMD high-performance computers enable the company to further its development of next-generation antibody therapeutics.

麦克莱恩补充说，AMD的高性能计算机使该公司能够进一步开发下一代抗体疗法。

Mark Papermaster, executive vice president and chief technology officer at AMD, said that Absci is at the forefront of AI-driven drug discovery and is proud to partner with AMD to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed.

AMD执行副总裁兼首席技术官马克·派马斯特（Mark Papermaster）表示，Absci处于人工智能驱动的药物发现的前沿，很荣幸与AMD合作，帮助进一步加速治疗学的突破，改变生物药物的开发方式。

'Absci's groundbreaking work with AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads,' Papermaster said in a statement.

Papermaster在一份声明中说：“Absci在人工智能药物发现方面的开创性工作非常适合AMD高性能计算解决方案和软件，这些解决方案和软件是为最苛刻的人工智能工作负载而设计的。”。

THE LARGER TREND

更大的趋势

In 2023,

2023年，

Absci announced a $247 million partnership with pharma giant

Absci宣布与制药巨头合作2.47亿美元

AstraZeneca

阿斯利康

that focuses on expediting the discovery of novel cancer treatments with the help of genAI technology.

它的重点是在genAI技术的帮助下加速发现新的癌症治疗方法。

The project leveraged Absci's Integrated Drug Creation platform, which combines scalable wet lab technologies with AI and facilitates optimization of multiple drug features pivotal for therapeutic advantages and AstraZeneca's oncology research and development knowledge. The aim of the collaboration was to utilize Absci's De Novo 'zero-shot' AI models that result in new, improved antibody therapies against cancer..

该项目利用了Absci的综合药物创建平台，该平台将可扩展的湿实验室技术与AI相结合，并有助于优化对治疗优势和阿斯利康肿瘤学研究与开发知识至关重要的多种药物功能。合作的目的是利用Absci的从头“零次”AI模型，从而产生新的，改进的抗癌症抗体疗法。。

That same year, Absci

同年，Absci

and Almirall, a global biopharmaceutical company focused on medical dermatology, entered into a drug discovery partnership aimed at developing and commercializing AI-designed therapeutics to fight chronic and debilitating dermatological diseases.

Almirall是一家专注于医学皮肤病学的全球生物制药公司，它成立了药物发现合作伙伴关系，旨在开发和商业化人工智能设计的治疗方法，以对抗慢性和衰弱的皮肤病。

The partnership combines Absci’s Integrated Drug Creation platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

该合作伙伴关系将Absci的综合药物创建平台与Almirall的皮肤病学专业知识相结合，旨在为患者提供改变生命的药物，标志着AI药物创建的又一步。

Absci

阿布斯基

and M2GEN, an oncology bioinformatics company, also announced a partnership to create new cancer medicines and bring them to market at speed. Absci’s generative AI drug creation platform will tap into M2GEN’s clinical and molecular data set, ORIEN AVATAR (AVATAR), to accelerate the creation of therapeutics for a range of malignancies and patient profiles, bringing AI drug creation to the fight against cancer..

肿瘤生物信息学公司M2GEN也宣布建立合作伙伴关系，开发新的癌症药物，并将其快速推向市场。Absci的生成性人工智能药物创建平台将利用M2GEN的临床和分子数据集Oren AVATAR（AVATAR），以加速一系列恶性肿瘤和患者概况的治疗方法的创建，从而将人工智能药物的创建带入抗癌斗争中。。

Tags:

标签：

Absci

阿布斯基

AMD

AMD公司

AI drug discovery

AI药物发现

More regional news

更多地区新闻

Trump revokes Biden's executive order on responsible AI development